Medpace (NASDAQ:MEDP) Trading Down 3.7% on Insider Selling

Medpace Holdings, Inc. (NASDAQ:MEDP) shares were down 3.7% on Thursday following insider selling activity. The stock traded as low as $530.96 and last traded at $554.93. Approximately 157,218 shares were traded during mid-day trading, a decline of 61% from the average daily volume of 408,083 shares. The stock had previously closed at $576.49.

Specifically, CEO August J. Troendle sold 668 shares of the company’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total value of $394,580.92. Following the sale, the chief executive officer directly owned 646,184 shares of the company’s stock, valued at approximately $381,694,426.96. This represents a 0.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO August J. Troendle sold 23,178 shares of Medpace stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $593.25, for a total value of $13,750,348.50. Following the transaction, the chief executive officer owned 652,550 shares of the company’s stock, valued at $387,125,287.50. The trade was a 3.43% decrease in their position. The disclosure for this sale is available in the SEC filing. In other news, CEO August J. Troendle sold 15,151 shares of the company’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $593.46, for a total value of $8,991,512.46. Following the sale, the chief executive officer owned 675,728 shares in the company, valued at $401,017,538.88. This represents a 2.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Analysts Set New Price Targets

MEDP has been the subject of several recent research reports. TD Cowen lifted their target price on shares of Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a report on Friday, October 24th. Barclays raised their target price on Medpace from $425.00 to $485.00 and gave the company an “underweight” rating in a research report on Friday, October 24th. Cowen restated a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Rothschild Redb lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Finally, Mizuho lifted their price target on shares of Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research report on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $487.18.

Medpace Price Performance

The firm has a 50 day moving average of $567.90 and a two-hundred day moving average of $452.68. The stock has a market cap of $15.44 billion, a PE ratio of 38.33, a PEG ratio of 2.05 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The firm had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company’s revenue was up 23.7% on a year-over-year basis. During the same period last year, the firm posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Medpace

A number of institutional investors have recently modified their holdings of the business. Clarkston Capital Partners LLC acquired a new stake in Medpace during the 2nd quarter worth approximately $40,569,000. Arkadios Wealth Advisors acquired a new position in shares of Medpace in the second quarter valued at approximately $327,000. Nordea Investment Management AB raised its stake in shares of Medpace by 4.8% during the second quarter. Nordea Investment Management AB now owns 61,125 shares of the company’s stock worth $19,067,000 after purchasing an additional 2,792 shares during the last quarter. Inspire Investing LLC purchased a new stake in shares of Medpace during the first quarter worth approximately $2,059,000. Finally, Truist Financial Corp lifted its holdings in shares of Medpace by 10.2% during the second quarter. Truist Financial Corp now owns 12,898 shares of the company’s stock worth $4,048,000 after purchasing an additional 1,197 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.